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Abstract 
In the field of bioanalysis, dried matrix spot sampling is increasingly receiving interest, as this 
alternative sampling strategy offers many potential benefits over traditional sampling, including matrix 
volume sparing properties. By using a microsampling strategy, e.g. volumetric absorptive 
microsampling (VAMS), the number of samples that can be collected from a patient can be increased, 
as a result of the limited sample volume that is required per sample. To date, no VAMS-based methods 
have been developed for the quantification of analytes in cerebrospinal fluid (CSF). The objective of 
this study was to develop and validate two LC-MS/MS methods for the quantification of paracetamol 
in dried blood and dried CSF, with both matrices sampled using VAMS. Both methods were fully 
validated based on internationally accepted guidelines. Paracetamol was chromatographically 
separated from its glucuronide and sulfate metabolites and no carry-over or unacceptable 
interferences were detected. The total precision (%RSD) was below 15% for all QC levels and accuracy 
(%bias) was below 7% (17% for the LLOQ of aqueous VAMS). The influence of the hematocrit on the 
recovery of blood VAMS samples appeared to be limited within the hematocrit range of 0.21 to 0.62. 
The blood VAMS samples were stable for 1 week if stored at 50 °C, and for at least 8 months when 
stored between -80 °C and room temperature. The aqueous VAMS samples were stable for at least 9 
months when stored between -80 °C and 4 °C, and for 1 month when stored at room temperature. 
Application of the methods on external quality control material and analysis of patient samples 
demonstrated the validity and utility of the methods and provided a proof of concept for the analysis 
of CSF microsamples obtained via VAMS devices. 
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1. Introduction 
Dried matrix spot (DMS) sampling is an alternative sampling strategy, typically using sample volumes 
less than 50 µL, which has many potential benefits over traditional sampling [1-5]. Therefore, this 
sampling strategy is receiving increasing interest from the bioanalytical field. Most methods using 
micro volumes of matrix have been developed and applied for the analysis of small molecules in blood- 
or plasma based samples. The most commonly used dried microsampling technique still remains dried 
blood spots (DBS), but over the years many innovative alternatives have been developed. One of these 
alternatives is an approach coined volumetric absorptive microsampling (VAMS). This device has been 
commercially available for several years (brand name Mitra™), and many research groups have 
developed methods for different types of clinical and toxicological determinations using this device 
[6]. The device (see Supplementary Electronic Material Figure S1) consists of a plastic handle and a 
polymeric tip, which absorbs a fixed volume of a given biofluid. The main advantage of the VAMS 
devices, when used for blood sampling, is that the hematocrit (Hct) of a sample does not influence the 
amount of blood that is absorbed [7, 8]. Thereby, the VAMS devices partially overcome the most 
discussed issue in DBS sampling, which is the Hct-based area bias [6, 9]. Besides its use for blood and 
plasma sampling, microsampling, including VAMS, can also be used for the analysis of other biological 
matrices, such as urine, oral fluid, and cerebrospinal fluid (CSF). 
Specifically for CSF, the number of methods and applications making use of DMS is limited [10, 11]. In 
certain specific situations dried CSF microsampling offers important advantages over traditional 
sampling, e.g. pharmacokinetic (PK) and toxicokinetic (TK) studies of drugs in CSF. By using a 
microsampling strategy, e.g. VAMS, the number of samples that can be collected from a patient can 
be increased, as a result of the limited sample volume that is required per sample. This low sample 
volume is even more beneficial when performing PK or TK studies in pediatric patient groups. 
Moreover, VAMS overcomes the need to handle micropipettes and accurate pipetting of small 
volumes in a clinical setting and facilitates sample storage and transport, which is especially interesting 
for analytes suffering from stability issues. As automated VAMS sample extraction and consecutive LC-
MS/MS analysis are most likely to be available in the near future, this would allow a uniform workflow 
for blood and CSF VAMS samples. To date, no VAMS-based methods have been developed for sampling 
and subsequent quantification of analytes in CSF. 
To establish a proof of concept for the use of VAMS for CSF microsampling, we chose paracetamol as 
a model compound. Paracetamol is one of the most widely used analgesics, for both children and 
adults. Many different research groups have studied the mechanism of action of paracetamol and 
recent studies have shown involvement of the central nervous system [12, 13]. Despite this insight, 
and the many studies that are being performed on the effect and the use of paracetamol in different 
patient groups, knowledge about its CSF disposition is still limited. The lack of PK studies can, at least 
partly, be explained by the high patient burden related to sampling and the relatively small CSF volume 
available for sampling. 
The objective of this study was to develop and fully validate methods for the quantification of 
paracetamol in dried blood and dried CSF utilizing VAMS. To the best of our knowledge, this is the first 
method in which analytes were quantified in dried CSF samples obtained via VAMS devices. 
2. Materials & Methods 
2.1. Chemicals and materials 
Paracetamol (pharmaceutical secondary standard), paracetamol sulfate (potassium salt), paracetamol 
β-D-glucuronide, formic acid (FA), the internal standard (IS) paracetamol-D4, calcium chloride, sodium 
phosphate dibasic (anhydrous), sodium phosphate monobasic (monohydrate) and bovine serum 
albumin were purchased from Sigma-Aldrich (Diegem, Belgium). LC-MS grade methanol was obtained 
from Biosolve (Valskenswaard, The Netherlands). Ultrapure water (18.2 MΩ resistivity) was generated 
in-house by a Synergy® Water Purification System (Merck Millipore, Overijse, Belgium). Potassium 
chloride and magnesium chloride (hexahydrate) were obtained from Merck (Darmstadt, Germany) and 
sodium chloride from VWR International (Radnor, PA, USA). Glucose was obtained from Acros Organics 
(Geel, Belgium). 10 µL VAMS devices (brand name Mitra™) were purchased from Neoteryx (Torrance, 
CA, USA). 
2.2. Standard solutions, calibrators, and quality control samples 
Stock solutions (10 mg/mL) were prepared by dissolving 10 mg of the paracetamol standard in 1 mL of 
methanol-water (50:50, v/v). Working solutions were prepared on the day of analysis by diluting the 
stock solution in water. Independently prepared solutions were used for the working solutions to 
prepare calibrators and quality control samples (QCs). For the IS, a stock solution (5 mg/mL) was 
prepared in a similar way and further diluted to 10 µg/mL with methanol. All stock solutions were 
stored at -20 °C. 
2.2.1. Blood samples 
Paracetamol free whole blood was collected from a healthy volunteer, using K2EDTA as 
anticoagulant. The blood was fortified with paracetamol by adding working solutions (non-
matrix spiked volume was 5% v/v). Calibrators were prepared at eight concentration levels in 
blank whole blood with concentrations of 0.10, 0.20, 0.50, 1.0, 5.0, 10.0, 50.0 and 100 µg/mL. 
QCs were prepared at four concentration levels: 0.10 µg/mL (lower limit of quantification, 
LLOQ); 0.25 µg/mL (Low QC); 7.5 µg/mL (Mid QC) and 80.0 µg/mL (High QC). VAMS was 
performed on the same day as the preparation of calibrators and QCs. To avoid overfilling of 
the device, only the lower part of the VAMS device was dipped in the blood samples. After the 
tip had turned completely red, an additional 2 s of sampling time was added. After sampling, 
the VAMS device was air-dried for at least 2 h prior to sample extraction. When samples were 
not analyzed on the day of preparation, they were stored in air tight bags containing desiccant. 
Blood with varying Hct levels was prepared by centrifuging an aliquot of the blood (5  min, 
5000 g) and by removing or adding plasma.  Hct of the donor blood was measured using a 
Sysmex XE-5000 hematology analyzer (Sysmex, Kobe, Japan). 
2.2.2. CSF samples 
No blank CSF was available for the preparation of calibrators and QCs. Therefore, water was 
evaluated (see 2.5 Method validation) as an alternative matrix replacing blank CSF. Calibrators 
and QCs were prepared by spiking water with the paracetamol working solutions. Calibrators 
were prepared at eight concentration levels: 0.10, 0.20, 0.50, 1.0, 5.0, 10.0, 20.0, and 
40.0 µg/mL. QCs were prepared at the same concentration levels as the blood QC samples, 
except for the High QC (35.0 µg/mL). For the absorption of blanks, calibrators and QCs onto the 
VAMS device tip, the lower part of the tip was dipped in the fluid for 6  s, as recommended by 
the manufacturer. After sampling, the VAMS device was air-dried for at least 2 h prior to sample 
extraction. When samples were not analyzed on the day of preparation, they were stored in air 
tight bags containing desiccant. 
2.3. Sample preparation 
VAMS sampler tips were removed from the handle and put into a 2 mL cup and extracted by 
adding 300 µL of extraction solvent (methanol-water-FA, 80:20:0.01, v/v/v), containing the IS 
(0.04 µg/mL). The extraction temperature was optimized by the evaluation of peak area ratios 
after extraction at 22 °C, 37 °C and 60 °C. For this evaluation, blood VAMS samples, with 
medium (0.44) and high (target value 0.60) Hct and spiked with paracetamol (1.0 µg/mL), were 
analyzed for each condition (n=3). The tips were extracted for 15 min by shaking in a 
Thermomixer comfort (Eppendorf, Hamburg, Germany) (1400 rpm), followed by centrifugation 
at ambient temperature for 10 min at 10000 g. Next, 250 µL of the supernatants was 
transferred to a vial and diluted with 750 µL of water (0.01 % FA). Injection volumes onto the 
UPLC® column were 3 µL for blood samples and 4 µL for CSF samples. 
2.4. Liquid chromatographic and mass spectrometric conditions 
A Waters Acquity UPLC® system (Waters, Milford, MA, USA) coupled to a SCIEX API 4000™ triple 
quadrupole mass spectrometer (SCIEX, Framingham, MA, USA) equipped with a TurboIonSpray® 
source was used for all experiments. The liquid chromatography tandem mass spectrometry 
(LC-MS/MS) system was controlled by SCIEX Analyst (version 1.6.2) and Waters Acquity console 
software. 
For the chromatographic separation of paracetamol and its metabolites, a Waters Acquity 
UPLC® HSS-T3 column (100 mm x 2.1 mm, 1.8 µm particle size) was used, equipped with a 
corresponding Waters VanGuard pre-column (5 mm x 2.1 mm; 1.8 µm particle size), held at 
45 °C and using a gradient mobile phase consisting of water-methanol-FA (95:5:0.01, v/v/v) (A) 
and methanol-water-FA (95:5:0.01, v/v/v) (B) with a flow rate of 0.55 mL/min. Mobile phase 
was held at 20% B for 0.7 min, increased linearly to 66% B over 1.3 min, further increasing 
linearly to 95% B over 0.2 min, held at 95% B for 1 min, followed by an immediate return to 
20% B and re-equilibrating at 20% B for 1 min, yielding a total runtime of 4.2 min. 
The mass spectrometer was operated in positive electrospray ionization (ESI) mode and multiple 
reaction monitoring (MRM). The mass transitions were m/z 152.04 to m/z 110.20 and to 
m/z 93.00 respectively for the quantification and qualification ion pairs of paracetamol. All 
MRM transitions, together with compound-specific parameters, are listed in the Electronic 
Supplementary Material Table S1 and source and gas parameters are tabulated in Table S2.  
2.5. Method validation 
The methods and acceptance criteria used for method validation were based on U.S. Food and 
Drug Administration (FDA) and European Medicines Agency (EMA) guidelines  for bioanalytical 
method validation [14, 15] The validation encompassed an evaluation of the following 
characteristics: selectivity, carry-over, calibration model, precision, accuracy, matrix effect 
(ME), recovery, Hct effect, stability and dilution integrity. In each analytical run a control blank 
(i.e. VAMS sample prepared from blank matrix and processed with extraction solvent that does 
not contain the IS), a zero sample (i.e. VAMS sample prepared from blank matrix and extracted 
with extraction solvent including the IS), and QC samples were included. 
Since no analyte-free CSF was available, we investigated whether water was suitable to be used 
as a surrogate matrix for CSF for the preparation of blanks, calibrators and QCs. For this 
purpose, patient CSF samples (n=6), containing paracetamol, were used. First, VAMS samples 
were made from CSF samples and from the same CSF samples diluted 1/10 in water, the latter 
resulting in overall aqueous samples. As a next step, both the original and diluted VAMS 
samples were analyzed against a calibration curve obtained by VAMS samples prepared from 
spiked water. For the evaluation, the %bias (diluted vs. original; taking into account the dilution 
factor) and the relative standard deviation (%RSD) were calculated. Acceptance criteria were 
±10% for the mean %bias and 15% for the %RSD [14, 15]. 
Selectivity was assessed by analysis of analyte-free blood samples from 6 individual donors for 
blood samples. For CSF samples, blank artificial CSF, prepared in-house, was used (see Electronic 
Supplementary Material Table S3 for composition). In addition, transition ratios were compared 
between calibrators and QCs (n=16) on the one hand, and patient CSF VAMS samples (n=55) on 
the other hand. Absence of interfering compounds was accepted if the transition ratio of the 
sample was ±20% of the average transition ratio of the calibrators and QCs. Furthermore, 
separate standard solutions were prepared from the metabolites paracetamol glucuronide and 
paracetamol sulfate (50 ng/mL for all compounds) to investigate whether these metabolites 
interfered with the paracetamol assay by monitoring of the paracetamol channel. These 
metabolites were not determined qualitatively nor quantitatively in this method. Absence of 
interfering components was accepted if the response at the retention time of paracetamol was less 
than 20% of the LLOQ for paracetamol and 5% for the IS [14, 15]. 
Carry over was assessed by injection of blank solvent (water) after the highest calibrator (n=4) using 
the same acceptance criteria as for selectivity [14, 15]. 
Calibration lines were constructed by plotting the ratio of the analyte area and IS area versus the 
nominal concentration. To determine the best fitting calibration model, six eight-point calibration 
curves were constructed over a total of four different days. An F-test was performed to investigate 
homoscedasticity (α=1%) at the highest and lowest calibrator level. Selection of the calibration model 
was based on the calculation of the sum % residual error (%RE) and a plot of the %RE against the 
nominal concentrations. A linear and a quadratic regression model were evaluated with or without 
weighing factors (1/x, 1/x², 1/y, 1/y², 1/√x and 1/√y). The calibration model with the lowest %RE and 
that showed no trend in the %RE plot was chosen. To test the selected models for goodness of fit, the 
%bias of the back-calculated concentrations of the calibrators from their nominal value was 
determined. The %bias should be less than 15% (and 20% for the LLOQ) for 75% of all calibrators to 
accept the chosen model [14, 15]. 
The accuracy of the methods was assessed by calculating the percent difference from the 
nominal concentration (%bias). The intra-day and total assay precision (%RSD) was calculated 
using single factor analysis of variance (ANOVA), according to the CLSI EP05-A3 guideline [16]. 
When the intra-day %RSD exceeded the inter-day %RSD, the inter-day %RSD was set to zero for the 
calculation of the total precision. All QC levels were prepared and analyzed in duplicate on three 
different days (n=3x2). Accuracy and precision were considered acceptable if %RSD and %bias 
were less than 15% and ±20% for the LLOQ [14, 15]. 
The determination of ME and recovery was based on the approach suggested by Matuszewski  
et al. [17]. For the evaluation of ME in blood VAMS samples, analyte free blood from six 
individual donors was used (Hct values ranging from 0.43 to 0.47). Extracts (i.e. the 250  µL 
supernatants mentioned in 2.3), prepared from blank blood were spiked at concentrations 
corresponding to Low QC and High QC level in blood (B). Neat solvent (methanol -water-FA, 
20:80:0.01, v/v/v) was spiked at the same concentration levels (A). Absolute ME was calculated 
by dividing the peak area of (B) by the peak area obtained from (A), multiplied with 100% (n=6). 
Internal standard compensated ME was calculated similarly by taking into account the IS peak 
area for (A) and (B). The relative ME was determined by calculation of the %RSD and should not 
exceed 15%. For the evaluation of recovery, water and blood with medium (0.40) Hct were 
spiked at Low QC and High QC level before (C) and after (B) extraction. Recovery was 
determined by dividing the peak area ratio of (C) by the peak area ratio of (B) multiplied with 
100% (n=6). While no acceptance criteria were set for the recovery, %RSD must be less than 15% 
[14]. To investigate the effect of the Hct of a sample on the recovery, blood VAMS samples with 
low (0.21), intermediate (0.30 and 0.50) and high (0.62) Hct were also prepared (n=6). The mean 
recovery of the VAMS samples with a Hct of 0.40 was normalized to 100%, and a relative 
recovery was calculated for all Hct levels by dividing the mean calculated concentration by the 
mean calculated concentration at Hct 0.40. For the CSF VAMS samples, ME was assessed via an 
evaluation of the IS peak area in 55 patient samples, compared to the IS peak area of calibrators 
and QCs (n=16).  
Short- and long-term stability of VAMS was assessed by analyzing VAMS samples spiked at Low 
QC and High QC level prepared in blood and water (for CSF) at time point zero (t 0) and after 1 
week at 50 °C, 9 months at 4 °C, 8 and 9 months at room temperature (RT) for blood and 
aqueous VAMS samples respectively, 9 months at -20 °C, and 9 months at -80 °C (n=3; duplicate 
measurements). VAMS samples were analyzed against a freshly prepared calibration curve. The 
mean concentration of the QC samples at a given storage condition should be within ±15% from 
the concentration at t0  [14, 15]. Furthermore, the stability of processed samples in the 
autosampler (held at 4 °C) for one week, after two freeze-thaw cycles and after 1 week at -20 °C 
was determined (n=3; duplicate measurements). 
The calibration range encompasses the therapeutic range in blood, but higher blood 
concentrations can be found in patients with a paracetamol intoxication [18]. We therefore 
investigated whether final extracts of samples above the upper limit of quantification (ULOQ) 
can be safely diluted. Blank whole blood and water were spiked with paracetamol at 
concentrations above the ULOQ (150 µg/mL and 300 µg/mL for blood and 60 µg/mL and 
125 µg/mL for water), VAMS samples were made and processed as described above. The final 
extracts were diluted 2 fold and 5 fold with water (0.01% FA) (n=6). With these dilution factors 
the peak area of the IS was still high enough to be integrated accurately. The peak area of the 
IS was multiplied with the dilution factor and used to determine the ratio analyte area/IS area. 
This way the concentration of the diluted extracts can be calculated via the calibration curve. 
Finally, the concentrations found were multiplied with the dilution factor. The maximum 
acceptable %bias and %RSD was 15%. 
Statistical analyses were performed with GraphPad Prism version 7.02 and Microsoft Excel 
2016, where necessary. 
2.6. Application 
For an objective evaluation of our method we applied it on QCs based upon external quality 
control (EQC) material. The available EQC material, Liquichek™ Therapeutic Drug Monitoring 
Control (TDM) (Bio-Rad, California, USA), was serum-based. Hence, , in order to somewhat mimic 
the matrices of interest as closely as possible that are to be analyzed with our method , blood 
QCs were prepared by replacing 250 µL of plasma (from a total blood volume of 1  mL) with 
250 µL of the EQC material. For the generation of CSF QCs the EQC material was diluted 1/10 
with water. This procedure was carried out for all three available levels of EQC material, 
resulting in nominal concentrations of 4.0, 10.1, and 32.8 µg/mL and 1.6, 4.0, and 13.1 µg/mL 
for blood QCs and CSF QCs respectively. VAMS were made from these QCs and processed as 
described above. 
As a proof of concept, blood and CSF VAMS samples from a patient admitted to the pediatric 
intensive care unit receiving intravenous paracetamol, were analyzed. Five blood VAMS 
samples and five CSF VAMS samples were collected at consecutive time points. At the pediatric 
intensive care unit, a small amount of arterial blood and CSF (via an external ventricular drain) 
were collected, after which VAMS samples were immediately prepared on-site as described in 
section 2.2.1 and 2.2.2. These samples were stored at room temperature for a maximum of 2 
weeks, and then kept at -80 °C until analysis. This study was approved by the Ethics Committee 
of Ghent University Hospital (B670201629325). Informed consent was provided by their parents 
or their legal representative. 
3. Results & Discussion 
3.1. Sample preparation 
As it is known that extraction of VAMS may be subject to Hct-dependent recovery issues [6, 9, 19] , 
we evaluated three different extraction temperatures (22 °C, 37 °C and 60 °C) by comparing peak 
area ratios of spiked VAMS samples (1.0 µg/mL) with intermediate (0.44) and high (target value 0.60) 
Hct (n=3). As depicted in Figure 1, there were no major differences in recovery over the different 
conditions. Furthermore, the only statistically significant difference detected was between 
extraction at 22 °C and 60 °C for the intermediate Hct VAMS samples. Although statistically 
significant, this difference was limited (0.362 vs. 0.384) and therefore we opted for 22 °C as 
extraction temperature. 
The choice of the extraction solvent (methanol-water-FA, 80:20:0.01, v/v/v) was based on a 
previously published method and was not further optimized since the desired sensitivity was 
reached with this procedure [9]. Furthermore, the %RSD in the experiment described above was 
below 8% for all conditions tested, demonstrating the reproducibility of the extraction. The same 
extraction conditions for blood VAMS samples were also applied for the analysis of CSF VAMS 
samples. 
3.2. Method validation 
The first step in order to validate the developed method was the evaluation of water as a surrogate 
matrix for blank CSF, since it was not possible to obtain the latter in sufficient quantities. To this end, 
we compared the results obtained from neat (undiluted) CSF from paracetamol-treated patients 
with those from CSF that had been diluted 10-fold in water, both against a calibration line set-up in 
water. All the diluted and undiluted samples fell within the calibration range. This approach is based 
on the publication of Matuszewski about the measure of relative ME via standard line slopes [20]. 
After correction for the dilution, the mean difference in concentrations found for diluted and 
undiluted samples was 3.33%, with a %RSD of 7.71%. These results were well within the predefined 
acceptance criteria (±10% bias and <15% RSD), which were based on the EMA criteria for the 
assessment of ME [14]. Although this approach does not give absolute values for ME and recovery 
in both matrices (i.e. CSF VAMS samples and aqueous VAMS samples), the equality of the process 
efficiency (a combination of matrix effect and recovery) for aqueous and CSF VAMS samples 
analyzed with this method can be demonstrated based upon an experiment with real-life patient 
samples. As the values obtained for neat and diluted samples (after taking into account the 10-fold 
dilution factor) were within 13% and as no consistent bias was observed after the dilution of CSF in 
water, it can be concluded that VAMS devices absorb the same volume of water and CSF. Therefore, 
we can safely use water as an alternative matrix for the preparation of blanks, calibrators, and QCs 
for the bioanalytical validation of the method and for the analysis of patient CSF samples. 
No carry-over or unacceptable interferences were observed for both blood and artificial CSF VAMS 
samples. Representative chromatograms of blank artificial CSF and blood VAMS samples and QC 
samples spiked at LLOQ level are shown in Figure 2, together with a patient CSF VAMS sample and 
patient blood VAMS sample. The transition ratios of the patient samples (n=55) were all between 
97.9% and 103.4% of the average transition ratio of the calibrators and QCs (n=16), indicating no 
interferences are present in these patient samples. 
Paracetamol and its sulfate and glucuronide metabolites are chromatographically separated 
(respective retention times 0.93 min, 0.70 min and 0.60 min; Electronic Supplementary Material 
Figure ), which is necessary to eliminate interferences from these metabolites by in-source 
formation. The stability of paracetamol sulfate and paracetamol glucuronide in dried VAMS samples 
made from spiked rat blood has been evaluated previously by Denniff et al., and no response at the 
paracetamol retention time was observed after 72 h of drying [21]. Furthermore, Li et al. determined 
paracetamol, paracetamol sulfate and paracetamol glucuronide in DBS generated from spiked 
human blood [22]. Also there, no issues were seen with the stability of the sulfate and glucuronide 
metabolite after a longer storage period (27 days; RT). The same stability can be assumed for these 
compounds in human blood VAMS samples and CSF VAMS samples and was therefore not further 
investigated in this validation process. 
The calibration data for blood and CSF VAMS samples were heteroscedastic. For the quantification 
of paracetamol in VAMS devices made from blood samples, a quadratic regression model with 1/x2 
weighing gave the lowest %RE. Linear regression with 1/x 2 weighing was the second best option, 
however in the %RE plot a trend was seen. Therefore, the quadratic regression model was preferred. 
For the CSF VAMS samples, a linear model with a weighing factor 1/x 2 was the best fitting model 
based upon back-calculation of the concentrations of the calibrators. The selected regression models 
met the pre-set acceptance criteria [14, 15]. The calibration range chosen for both the CSF VAMS 
method and the blood VAMS method includes sub-therapeutic, therapeutic, and supra-therapeutic 
concentrations (in blood). Hence, these methods cannot only be used for the analysis of samples 
from patients receiving therapeutic concentrations of paracetamol, but also for overdose cases and 
for PK or TK studies. 
The accuracy, intra-day precision and total precision for QCs, analyzed in duplicate on three different 
days, fulfilled the predefined criteria (%bias and %RSD < 15%, 20% for LLOQ), as shown in Table 1.  
The absolute ME and IS-corrected ME for blood VAMS samples approximated 100% for both the Low 
QC and High QC level, indicating no significant enhancement or suppression of ionization. The relative 
ME fulfilled the predetermined acceptance criteria, with a maximum value of 3.8% (Table 1 Accuracy 
(%bias), intra-day and total precision (%RSD) and data for QC samples prepared at four concentration levels 





Total precision  
(%RSD) 
Blood     
LLOQ 3.1 8.5 16.7 
Low -0.67 11.7 11.7 
Medium 4.9 5.0 14.7 
High 4.2 2.8 7.8 
Water    
LLOQ 16.8 6.9 6.9 
Low 2.5 5.3 5.3 
Medium 6.0 4.5 4.5 
High -0.43 3.9 7.6 
 
Table 2). 
The experiment in which water was investigated as surrogate matrix for analyte free CSF showed that 
the process efficiency of aqueous VAMS samples and CSF VAMS samples is equivalent. A matrix effect 
experiment with spiked water (as was done for blood) was not performed, since this does not provide 
any additional relevant information for the validation of this method. The evaluation of IS areas 
between patient samples and aqueous calibrators and QCs resulted in an overall %RSD of 7.3%, 
demonstrating that no significant ion suppression or ion enhancement was present in these patient 
samples. In order to conclude this, we assumed that the effects of interfering compounds on the 
ionization are the same for the analyte and the IS, which can be assumed as the internal standard is a 
stably isotope labeled (D4) analogue of the analyte. 
The absolute recovery has been determined for blood VAMS samples derived from blood with 
intermediate Hct (0.40) and water spiked at Low QC and High QC level. Values (mean ± SD) obtained 
were 75±9% for the Low QC and 78±4% for High QC blood VAMS samples and 70±6% and 78±3% for 
Low and High QC aqueous VAMS samples respectively. For these calculations, it was not taken into 
account that only 250 µL out of 300 µL extraction solvent is used to proceed to the next step of the 
sample preparation. Therefore, the recovery value provides the relative amount of analyte recovered 
from the sample after the complete sample preparation process, and not solely the relative amount of 
analyte recovered from the VAMS sample during the extraction step. Hence the maximum obtainable 
recovery is 83.3% Statistical analysis via one-way ANOVA did not reveal any significant difference in 
recovery between the groups. 
Hct-dependent recovery is a well-known issue when using VAMS as a sampling device [6, 9, 19]. 
Furthermore, it is known that a high recovery minimizes the chance of a Hct-dependent recovery. In 
the experiments discussed by Abu-Rabie et al., paracetamol was even used as a case example of a 
compound that suffers from Hct-dependent recovery when using DBS as a sampling technique [23]. 
Moreover, as the IS is added in the extraction solvent, it cannot compensate for variations in recovery. 
We therefore evaluated the impact of the Hct on the recovery in more detail. Recoveries for VAMS 
samples derived from spiked blood with Hct values ranging from 0.21 to 0.62 were determined and 
compared to the recovery of blood samples with Hct 0.40. All samples were analyzed against a 
calibration curve with VAMS samples derived from spiked blood with Hct 0.40. 
Even though we noticed a trend towards decreasing recovery with increasing Hct values, only the 
recovery of the Low QC level VAMS samples with Hct 0.62 differed more than 15% (15.8%) from the 
recovery at Hct 0.40 (Figure 3). The difference is statistically significant (p = 0.0053) but the result is 
only just outside of the acceptance limit. These values are comparable with the results from 
Denniff et al. for the analysis of paracetamol in rat blood VAMS samples [21]. Therefore, we conclude 
that there is an impact of the Hct on the recovery, but overall this impact is limited and will not 
significantly affect the analytical result. If possible, adjustment of the Hct of the blood used to prepare 
calibrators to the median expected Hct of the patient population is recommended. This way the 
influence of the Hct on recovery will be reduced as much as possible. 
The stability in blood VAMS samples was found to be within the acceptance criteria after storage at 
50 °C for 1 week; -80 °C, -20 °C, and 4 °C for 9 months; and RT for at least 8 months. The stability in 
aqueous VAMS samples was within ±15% limits after storage at 4 °C, -20 °C, and -80 °C for 9 months. 
The stability at RT was within the acceptance criteria for aqueous VAMS samples stored up to 1 month. 
The results are summarized in Table 1 Accuracy (%bias), intra-day and total precision (%RSD) and data for 





Total precision  
(%RSD) 
Blood     
LLOQ 3.1 8.5 16.7 
Low -0.67 11.7 11.7 
Medium 4.9 5.0 14.7 
High 4.2 2.8 7.8 
Water    
LLOQ 16.8 6.9 6.9 
Low 2.5 5.3 5.3 
Medium 6.0 4.5 4.5 
High -0.43 3.9 7.6 
 
Table 2 Absolute and relative matrix effect at Low QC and High QC level in VAMS samples made from spiked 
blood from six different donors (n=6) 
QC Absolute matrix effect (mean %) Relative matrix effect (%RSD) 
 Without IS With IS Without IS With IS 
Low 
   (n=6) 
95 103 2.8 3.8 
High 
   (n=6) 
97 102 3.4 2.9 
 
Table 3. Overall, for blood VAMS, the data do not indicate any issue with stability, which is in line with 
earlier reports [21, 22]. In contrast, readily after four days, concentrations determined in aqueous 
VAMS samples stored at 50 °C had considerably decreased (30% and 32% of the concentrations 
measured at t0 for the Low QC and High QC respectively) and these values decreased even further after 
storage for seven days (Table 1 Accuracy (%bias), intra-day and total precision (%RSD) and data for QC 
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Table 3). Furthermore, also the aqueous VAMS samples stored for 9 months at RT showed a notable 
decrease in measured concentrations (56% and 57% of the concentrations measured at t0 for the Low 
QC and High QC respectively). As there is no reason to believe that there would be an issue with 
paracetamol stability as such, as demonstrated by the results from the blood VAMS samples, this 
apparent instability is most likely attributable to a recovery issue. A similar phenomenon was also 
described by Xie et al., where optimization of the extraction procedure led to an increased recovery 
and thereby elimination of an extractability-mediated recovery bias [24]. Our results demonstrate that 
it is indeed highly important to carefully evaluate the recovery, after different (long-term) storage 
conditions. Furthermore, these results indicate that an extractability-mediated recovery bias can be 
matrix-dependent. The underlying cause for this unexpected matrix-dependent finding is unknown, 
but might be related to an “aging-phenomenon” of VAMS. Indeed, it is known that, upon aging of 
unused VAMS, the speed at which a biofluid is absorbed decreases. The process which takes place 
upon storage of the aqueous matrix-filled VAMS might be similar to changes taking place in unused 
devices. However, further research is required to reveal the exact cause of this unexpected decreased 
extractability. To the best of our knowledge, we are the first to report on a matrix-dependent “aging-
phenomenon” in filled VAMS. Although these observations do demand caution, the extreme storage 
conditions evaluated here are not relevant for our applications, in which patient CSF VAMS samples 
are collected in a hospital setting where they are stored at room temperature (for a maximum of 2 
weeks), after which they are transported to the lab for further storage at -80 °C. Three sets of 
processed sample extracts from blood and aqueous VAMS samples (n=3; duplicate measurements), 
stored in the autosampler (4 °C) for 1 week, stored at -20 °C for 1 week and after 2 freeze-thaw cycles 
were re-analyzed. None of the conditions gave a decrease in concentration of more than 8%, with a 
maximum %RSD of less than 4% (see Electronic Supplementary Matrial Figure S3). 
Finally, a dilution integrity experiment showed that VAMS blood and aqueous samples can be diluted 
2-fold as well as 5-fold without compromising the accuracy and precision, as is shown in Table 1 
Accuracy (%bias), intra-day and total precision (%RSD) and data for QC samples prepared at four 





Total precision  
(%RSD) 
Blood     
LLOQ 3.1 8.5 16.7 
Low -0.67 11.7 11.7 
Medium 4.9 5.0 14.7 
High 4.2 2.8 7.8 
Water    
LLOQ 16.8 6.9 6.9 
Low 2.5 5.3 5.3 
Medium 6.0 4.5 4.5 
High -0.43 3.9 7.6 
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Table 3 Stability data for aqueous VAMS samples and blood VAMS samples. Samples were stored at 50 °C for 
1 week, and at room temperature, 4 °C, -20 °C and -80 °C for 8 or 9 months, (n=3; **n=2) measured in duplicate. 
Data are presented as the mean % ± %RSD of the concentration measured at time point zero. Samples from 
stability time points indicated with an asterisk (*) could not be quantified owing to a technical error. 
Storage 
condition 
Concentration of samples compared to time point zero  
(mean ± RSD, %) 
 Blood Water 
  Low QC High QC  Low QC High QC 
50 °C 7 d 102±8.3 94±3.3 7 d 16±6.9 9±13 
RT 1 m 110±5.5 98±3.4 1 m 90±7.6 88±6.9 
RT 8 m 106±5.1 108±6.0 9 m 56±6.8 57±6.5 
4 °C 9 m NA (*) 99±3.7 9 m 107±8.7 94±8.1 
-20 °C 9 m NA (*) 100±3.7 9 m 105±5.9 93±6.1 
-80 °C 9 m 96±13(**) 101±4.8 9 m 112±9.3 99±7.9 
RT: room temperature; NA: not available 
Table 4. A maximum %bias of 7.8% and maximum %RSD of 5.9% was found. The highest concentration 
of samples that can be quantified is thereby increased to 500 µg/mL for blood VAMS samples and 
200 µg/mL for CSF VAMS samples, which is sufficient for the purpose of this method. 
3.3. Application 
Since neither blood nor CSF based EQC material was available, serum based EQC material (Liquichek™ 
Therapeutic Drug Monitoring Control (TDM) Level 1, Level 2, and Level 3) was used to prepare 
blood and aqueous QC material and VAMS samples derived thereof. The calculated 
concentrations were compared to the nominal value and relative values are depicted in Figure 4. 
For the blood VAMS samples, all means and individual sample values were within the ±20% 
acceptance interval. Although for the aqueous VAMS samples 4/18 individual values had a %bias 
outside of the acceptance interval (with a maximum %bias of 26%), all means were within the ±20% 
acceptance criterium. The concentration range of these QCs (4.0-32.8 µg/mL in blood and 1.6-
13.1 µg/mL in water) covers therapeutically relevant concentrations. Therefore, this experiment, 
using lab-prepared QCs, starting from EQCs, supports the validity of our method. 
To have a proof of concept that the analysis of real life patient samples does not pose any 
unexpected issues, 5 blood VAMS samples and 5 CSF VAMS samples were analyzed. The samples 
were collected from a patient receiving treatment with intravenous paracetamol. The results, 
displayed in Figure 5, show that the concentration range of the method was suitable and all samples 
could be quantified. 
One point of attention  is that a visual evaluation of VAMS sample quality (e.g. under- and over-
filling) is difficult for a non-colored matrix like CSF. Therefore, an appropriate training of the staff 
responsible for the collection of study samples is highly recommended. 
4. Conclusion 
The use of microsampling strategies for the collection of patient samples is increasingly receiving 
interest, as these offer many advantages over traditional sampling. To date, the use of these 
microsampling strategies for the collection of CSF has remained limited. However, this approach can 
facilitate the implementation of drug PK and TK studies in CSF. 
In this study, LC-MS/MS methods were developed and validated for the quantitative analysis of 
paracetamol in blood and CSF VAMS samples. The methods fulfilled the pre-set validation 
acceptance criteria and their application on EQC material and patient samples demonstrated their 
validity. For the analysis of blood VAMS samples special attention was paid to the effect of the Hct 
on the recovery, which appeared to be limited. Furthermore, our study revealed that an 
extractability-mediated recovery bias can be matrix dependent and that long-term storage and/or 
storage at elevated temperature should be carefully evaluated when developing methods utilizing 
VAMS for sampling. 
The most important advantage of using VAMS for the collection of CSF is the increased number of 
samples that can be collected from a single patient without increased patient burden. As a next step, 
these methods will be used to measure paracetamol concentrations in blood and CSF VAMS samples 
from a larger number of pediatric patients.  
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Figure 1 Effect of the extraction temperature on the recovery of blood VAMS samples with intermediate (0.44) 
and high (target value 0.60) Hct. Extraction temperatures of 22 °C, 37 °C and 60 °C were evaluated by 
comparison of peak area ratios. Mean peak area ratio and SD are shown (n=3). Asterisk depicts significant 
statistical difference from extraction at 22 °C (p< 0.05, two sided t-test) 
 
Figure 2 Chromatograms obtained with the analysis of a blank blood VAMS sample (A), blank artificial CSF VAMS 
sample (B), spiked blood VAMS sample at LLOQ level (0.10 µg/mL) (C), spiked aqueous VAMS sample at LLOQ 
level (0.10 µg/mL) (D), patient blood VAMS sample (E), and patient CSF VAMS sample (F). Two transitions for 
paracetamol (APAP 1, blue line and APAP 2, red line) and two transitions for the IS (APAP-d4 1, green line and 
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Figure 3 Impact of the Hct on recovery. VAMS samples (Low QC and High QC level) were prepared from spiked 
blood with five different Hct values (target values 0.21, 0.30, 0.40, 0.50 and 0.62). The mean IS-corrected 
recovery of samples with Hct 0.40 is normalized to 100%. Mean (%) ± SD is shown. The dashed lines represent 
the ±15% acceptance limits. Asterisks depict statistically significant difference from Hct 0.40 (p < 0.05, two 
sided t-test) 
 
Figure 4 Analysis of QC samples derived from external quality control material. The obtained concentrations 
are depicted as percentage of the nominal value. Individual values (open squares and open circles) and mean 
values (black squares) are presented for each level of blood VAMS samples and aqueous VAMS samples (n=6). 
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Figure 5 Analysis of patient CSF VAMS samples (n=5; dashed black line) and blood VAMS samples (n=5; solid 
grey line) with the measured paracetamol concentrations shown over time. The shaded area represents the 
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Table 1 Accuracy (%bias), intra-day and total precision (%RSD) and data for QC samples prepared at four 





Total precision  
(%RSD) 
Blood     
LLOQ 3.1 8.5 16.7 
Low -0.67 11.7 11.7 
Medium 4.9 5.0 14.7 
High 4.2 2.8 7.8 
Water    
LLOQ 16.8 6.9 6.9 
Low 2.5 5.3 5.3 
Medium 6.0 4.5 4.5 
High -0.43 3.9 7.6 
 
Table 2 Absolute and relative matrix effect at Low QC and High QC level in VAMS samples made from spiked 
blood from six different donors (n=6) 
QC Absolute matrix effect (mean %) Relative matrix effect (%RSD) 
 Without IS With IS Without IS With IS 
Low 
   (n=6) 
95 103 2.8 3.8 
High 
   (n=6) 
97 102 3.4 2.9 
 
Table 3 Stability data for aqueous VAMS samples and blood VAMS samples. Samples were stored at 50 °C for 
1 week, and at room temperature, 4 °C, -20 °C and -80 °C for 8 or 9 months, (n=3; **n=2) measured in duplicate. 
Data are presented as the mean % ± %RSD of the concentration measured at time point zero. Samples from 
stability time points indicated with an asterisk (*) could not be quantified owing to a technical error. 
Storage 
condition 
Concentration of samples compared to time point zero  
(mean ± RSD, %) 
 Blood Water 
  Low QC High QC  Low QC High QC 
50 °C 7 d 102±8.3 94±3.3 7 d 16±6.9 9±13 
RT 1 m 110±5.5 98±3.4 1 m 90±7.6 88±6.9 
RT 8 m 106±5.1 108±6.0 9 m 56±6.8 57±6.5 
4 °C 9 m NA (*) 99±3.7 9 m 107±8.7 94±8.1 
-20 °C 9 m NA (*) 100±3.7 9 m 105±5.9 93±6.1 
-80 °C 9 m 96±13(**) 101±4.8 9 m 112±9.3 99±7.9 
RT: room temperature; NA: not available 
Table 4 Accuracy (%bias) and precision (%RSD) of VAMS blood and CSF samples diluted 2-fold and 5-fold (n=6) 
Dilution factor Accuracy (% bias) Precision (%RSD) 
Blood   
2 -7.8 4.4 
5 -4.8 4.8 
Water   
2 1.0 5.4 
5 7.5 5.9 
  
Electronic Supplementary Material 
Table S1 Multiple reaction monitoring transitions and compound-specific MS parameters for paracetamol and 















Paracetamol 152.04 110.2 51 10 23 8 
0.93 
  93.0 51 10 31 6 
        
Paracetamol-D4 156.06 114.2 51 10 23 8 
0.92 
  97.0 51 10 27 6 
DP: declustering potential, EP: entrance potential, CE: collision energy, CXP: collision cell exit potential, 
Tr: retention time 
Table S2 Source and gas parameters 
CAD 10 psi 
CUR 30 psi 
GS 1 50 psi 
GS 2 70 psi 
ISV 5500 V 
TEM 500 °C 
CAD: collisionally activated dissociation gas, CUR: curtain gas, GS 1: nebulizer gas, GS 2: turbo gas, ISV: IonSpray 
voltage, TEM: temperature of the turbo gas 
Table S3 Composition and electrolyte concentrations of artificial CSF prepared in-house 
Composition Electrolyte concentration (mM) 
NaCl 8.66 g/L Na 150 
KCl 0.224 g/L K 3.0 
CaCl2 0.155 g/L Ca 1.4 
MgCl2·6H2O 0.163 g/L Mg 0.8 
Na2HPO4·7H2O 0.214 g/L P 1.0 
NaH2PO4·H2O 0.027 g/L Cl 155 
Glucose 10 mM   
Albumin 350 mg/L   
 
Figure S1 Blood-filled volumetric absorptive microsampling (VAMS) device 
 
 
Figure S2 Reconstructed chromatogram of three different injections of standard solutions of paracetamol 
glucuronide (50 ng/mL), paracetamol sulfate (50 ng/mL) and paracetamol (50 ng/mL). Transitions monitored 
are m/z 326.11 → m/z 113.10, m/z 229.86 → m/z 149.90 and m/z 152.04 → m/z 110.20 for paracetamol-

























Figure S3 Evaluation of the stability of processed blood and aqueous VAMS sample extracts. The difference 
with the concentration a time point zero (t0) is shown. Means (%) and SD are displayed (n=3; duplicate 
measurements). Sample extracts were stored in the autosampler (4 °C) and at -20  °C for 1 week (“processed 
sample stability”). A third set of sample extracts had undergone two freeze-thaw cycles (“free thaw stability”). 
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